EW vs LIVN
EW: Edwards Lifesciences is a leading developer of transformative structural heart technologies, including transcatheter heart valve replacement and repair solutions. LIVN: LivaNova is a medical technology company specializing in innovative cardiovascular and neuromodulation therapies to improve patient lives.
Side-by-side fundamentals
| Metric | EW | LIVN | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $83.82 | $78.61 | |
| Market cap as of 2026-07-24 | $47.9B | $4.3B | |
| P/E as of 2026-07-24 | 43.73 | 40.13 | LIVN lower |
| PEG as of 2026-07-24 | 2.00 | 3.92 | EW lower |
| Net margin as of 2026-07-24 | +17.4% | +7.5% | EW higher |
| Gross margin as of 2026-07-24 | +77.9% | +67.5% | EW higher |
| Operating margin as of 2026-07-24 | +17.1% | +13.1% | EW higher |
| ROE as of 2026-07-24 | +10.6% | +9.1% | EW higher |
| ROA as of 2026-07-24 | +8.2% | +4.2% | EW higher |
| Debt / equity as of 2026-07-24 | 0.06 | 0.24 | EW lower |
| Revenue growth (YoY) as of 2026-07-24 | +13.8% | +12.4% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +10.8% | Tie |
| Beta as of 2026-07-24 | 0.84 | 0.88 | |
| 1-year return as of 2026-07-23 close | +10.6% | +78.2% | LIVN higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.